Comparison of Intralase and Visumax Femtosecond Laser for Laser In Situ Keratomileusis
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Emtosecond lasers are used in cutting the flap in LASIK procedures (laser corrective surgery for refractive error). Their use has decreased the incidence of serious complications when compared to the use of microkeratomes(mechanical blades). The commonest femtosecond laser currently used is 'Intralase'. A newer femtosecond laser 'Visumax' (Zeiss) is now available and differs from the Intralase in that it does not interfere with the curvature of the cornea when creating the flap. The Intralase applanates the cornea flat during flap creation which causes the intraocular pressure to be higher. Both Intralase and Visumax lasers are available to patients and surgeons to use at SNEC. The aim of the investigators study is to compare the two lasers in a randomization of left and right eyes in the same patient. The investigators want to measure any difference that the lower intraocular pressure may have during the creation of the flap. This will be measured with a questionaire on patient experience during the procedure and the outcomes of vision, refraction, contrast sensitivity, wave-front analysis, tear function,corneal sensation and flap thickness measured with anterior segment OCT during the post-operative follow up period. To date no-one has compared the use of these two femtosecond lasers. Both lasers are currently used clinically for flap creation at SNEC.
| Condition |
|---|
|
Myopia |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Prospective |
- Visual Acuity [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]
- complications [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]
- Subjective questionnaire [ Time Frame: 1 weekd ] [ Designated as safety issue: No ]
- Corneal Sensation [ Time Frame: 3 months ] [ Designated as safety issue: No ]
- Tear function [ Time Frame: 3 months ] [ Designated as safety issue: No ]
- Wavefront analysis [ Time Frame: 3 months ] [ Designated as safety issue: No ]
- Contrast Sensitivity [ Time Frame: 3 months ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 45 |
| Study Start Date: | January 2010 |
| Estimated Study Completion Date: | December 2010 |
| Estimated Primary Completion Date: | August 2010 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
1 IntraLase flaps
Patients who have undergone flap creation with IntraLase laser
|
|
2 Visumax flaps
Patients who have undergone flaps created with Visumax laser
|
Eligibility| Ages Eligible for Study: | 21 Years to 60 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Myopic patients presenting to refractive service eligible for LASIK
Inclusion Criteria:
- 21 years of age or older.
- Cycloplegic spherical equivalent of >-1.00D
- Refractive cylinder -4.00 D or less.
- Best spectacle corrected visual acuity (BSCVA) of 6/12 or better in BOTH eyes.
- Spherical or cylindrical error has progressed at -0.50D or less per year from date of baseline measurement.
- Contact lens wearers must have removed contact lenses at least two (2) weeks before the baseline measurement.
- No evidence of irregular astigmatism on corneal topography.
- Available to attend post-operative examinations for a 3 month period.
Exclusion Criteria:
- Progressive or unstable myopia and/or astigmatism.
- Clinical or corneal topographic evidence of keratoconus.
- Residual, recurrent or active ocular disease such as uveitis, severe dry eyes, severe allergic eye disease, glaucoma, visually significant cataract and retinal disease.
- Previous corneal surgery or trauma within the corneal flap zone.
- Patent corneal vascularization within 1mm of the corneal flap zone.
- Taking systemic medications likely to affect wound healing, such as corticosteroids and antimetabolites.
- Systemically immunocompromised.
- Systemic disease likely to affect wound healing, such as diabetes, connective tissue disease and severe atopy.
- Pregnant or nursing.
Contacts and Locations| Contact: Donald Tan, MD, FRCS | 6322 4533 | snecdt@pacific.net.sg |
| Contact: Jod Mehta, MD FRCS | 6322 4533 | jodmehta@gmail.com |
| Singapore | |
| Singapore National Eye Centre | Recruiting |
| Singapore, Singapore, 168751 | |
| Contact: Donald Tan snecdt@pacific.net.sg | |
| Contact: Jod Mehta jodmehta@gmail.com | |
| Sub-Investigator: Jod Mehta | |
| Principal Investigator: | Donald Tan | Singapore National Eye Centre |
More Information
No publications provided
| Responsible Party: | Professor D Tan, Singapore National Eye Centre / SIngapore Eye Research Institute |
| ClinicalTrials.gov Identifier: | NCT01252654 History of Changes |
| Other Study ID Numbers: | R683/33/2009, Other |
| Study First Received: | May 10, 2010 |
| Last Updated: | December 1, 2010 |
| Health Authority: | Singapore: Singhealth Centralised IRB |
Keywords provided by Singapore Eye Research Institute:
|
Lasik Femtosecond Laser Visumax |
IntraLase Myopia Myopic Patients undergoing LASIK |
Additional relevant MeSH terms:
|
Myopia Refractive Errors Eye Diseases |
ClinicalTrials.gov processed this record on May 16, 2013